Skip to main content

Table 1 Baseline characteristics of 249 patients enrolled in the DRV/COBI cohort

From: Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: results from a large multicentre observational prospective cohort (SCOLTA)

  Dual therapy Triple therapy P
N % N %
Enrolled patients 72 28.9 177 71.1  
Female 28 38.9 39 22.0 0.007
Risk factor for HIV acquisition
 Sexual 30 41.7 103 58.2  
 Intravenous drug use 29 40.3 46 26.0  
 Transfusion/vertical/unknown 13 5.6 28 1.1 0.04
Ethnicity
 Caucasian 70 97.2 165 93.2  
 Other 2 2.8 12 6.8 0.21
 Naive 1 1.4 8 4.5 0.45
CDC stage
 A 15 20.8 47 26.6  
 B 40 55.6 68 38.4  
 C 17 23.6 62 35.0 0.59*
HIVRNA > 50 copies/mL at T0** 11 15.5 12 7.1 0.04
Previous regimen including**
 PI 61 85.9 161 95.3 0.01
 NNRTI 15 21.1 4 2.4 < 0.0001
Hypercholesterolemia 44 61.1 77 43.5 0.03
Hypertriglyceridemia 11 15.3 30 16.9 0.67
  Mean or median SD or IQR Mean or median SD or IQR  
Mean age, SD (years) 50.2 10.8 48.2 10.1 0.17
Mean CD4, SD (cells/mm3) 625 381 581 343 0.37
Median time on PI, IQR (years) 8.8 5.9–11.5 5.8 2.5–10.0 0.001
Median time on NNRTI, IQR (years) 2.4 0.9–4.8 1.6 0.1–5.3 0.12
Median time on ART, IQR (years) 18.1 7.8–21.0 9.0 3.2–17.9 < 0.0001
Mean eGFR, SD (mL/min) 94.2 20.3 96.3 23.6 0.50
  1. SD: Standard deviation; PI: protease inhibitors; NNRTI: non nucleoside reverse transcriptase inhibitors; IQR: interquartile range; eGFR: estimated glomerular filtration rate
  2. * Mantel–Haenszel Chi square test
  3. ** Experienced patients, n = 240